Media headlines about Benitec Biopharma Limited (NASDAQ:BNTC) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Benitec Biopharma Limited earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.6978453392833 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Benitec Biopharma Limited (NASDAQ BNTC) traded down 13.93% on Friday, hitting $2.41. 62,494 shares of the stock were exchanged. Benitec Biopharma Limited has a 52 week low of $1.30 and a 52 week high of $5.48. The company’s 50-day moving average is $2.15 and its 200-day moving average is $2.31. The company’s market cap is $24.72 million.

A number of research firms have recently commented on BNTC. ValuEngine raised shares of Benitec Biopharma Limited from a “sell” rating to a “hold” rating in a research note on Friday, September 22nd. Maxim Group reaffirmed a “hold” rating on shares of Benitec Biopharma Limited in a research note on Wednesday, August 30th.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/benitec-biopharma-limited-bntc-given-daily-news-sentiment-rating-of-0-09/1617646.html.

About Benitec Biopharma Limited

Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.

Insider Buying and Selling by Quarter for Benitec Biopharma Limited (NASDAQ:BNTC)

Receive News & Ratings for Benitec Biopharma Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.